KRAS and non-small cell lung carcinoma: Similar to sotorasib, adagrasib is the second selective KRAS G12C inhibitor to have been shown with clinical efficacy against patients with previously treated KRAS G12C-mutated NSCLC, according to the results of the KRYSTAL-1 multi-cohort phase II study (NCT03785249) [30].